Fig. 3

EGFR/CDK5 signaling is activated in E-cadherin-expressing cells and can be inhibited by roscovitine. a Proliferation assay performed on control (CO) or E-cadherin silenced OAW42 cells (E-cadh-1/2) grown in the presence of EGF and treated with roscovitine alone (20 μM), or gefitinib (10 μM) or with both drugs. Asterisks indicate statistically significant values by Student’s t test. A representative experiment is shown of three performed. b Western blotting on total cell lysates from OAW42 and OVCAR5 cells transiently transfected with control (−) or a pool (+) of E-cadherin siRNAs (siE-cadh-1/2), starved and then stimulated with EGF 20 ng/ml and treated with roscovitine. Immunoblottings were performed with Abs against the proteins reported on the left. β-actin was used as control of gel loading. c Upper panel: western blotting on total cell lysates from OVCAR5, OAW42, SKOV3 and NL3507 cells. Immunoblottings were performed with Abs against the proteins reported on the left. β-actin was used as control of gel loading. Lower panel: cell viability assay on OVCAR5, OAW42, SKOV3 and NL3507 cells treated with roscovitine (2, 5, 10, 20, 40 μM) up to 96 h. Each point represents the mean of three replicates. Error bars, SD